Avalon Technologies Publication of Earnings Call Transcript for Q3 FY26
Avalon Technologies Limited has officially published the transcript for its Earnings Call concerning the financial performance of the Quarter…
Patanjali Foods Limited Board Approves Unaudited Results for Q3 FY26, Revenue Hits Record High
Patanjali Foods Limited (PFL) announced its unaudited standalone and consolidated financial results for the quarter and nine months ended…
Canara Bank Announcement of Revised Marginal Cost of Funds Based Lending Rate (MCLR) Effective February 12, 2026
Canara Bank has formally notified the stock exchanges regarding a revision in its Marginal Cost of Funds Based Lending Rate (MCLR) structure.…
Alembic Pharmaceuticals Q3 FY’26 Earnings Call Transcript Highlights Strong Revenue Momentum
Alembic Pharmaceuticals reported a solid Q3 FY’26, with revenue growing 11% YoY to INR 1,876 crores, driven by volume expansion and…
RBL Bank RBI Approves ICICI Prudential AMC Group to Acquire Up to 9.95% Stake
The Reserve Bank of India (RBI) has granted approval to ICICI Prudential Asset Management Company Limited (I-Pru AMC) and its group entities…
Patanjali Foods Limited Approval and Grant of 5.27 Million Employee Stock Options Under ESOP 2023
Patanjali Foods Limited announced the approval of “ESOP Grant IV” comprising 52,71,793 Employee Stock Options (ESOPs) under its existing ESOP…
Eternal Limited Clarification on Zomato AI-Powered Hotline Launch for Delivery Partners
Eternal Limited, formerly known as Zomato Limited, issued a clarification regarding recent news concerning the launch of an AI-powered…
IDFC FIRST Bank RBI Approves 9.95% Stake Acquisition by ICICI Prudential AMC
The Reserve Bank of India (RBI) has granted in-principle approval to ICICI Prudential Asset Management Company Limited and its group entities…
Concord Biotech Limited Board Approves Q3 FY26 Unaudited Results and Appoints New Company Secretary
Concord Biotech announced the outcome of its Board meeting held on February 11, 2026. The Board approved the Unaudited Standalone and…
AstraZeneca Pharma India Reports 39% Growth in Q3 FY26 Driven by Portfolio Strength and Regulatory Approvals
AstraZeneca Pharma India announced a robust 39% growth for Q3 FY’25-26 (Oct-Dec ’25), with total revenue reaching INR 6,115.7 Mn.…